Hsbc Holdings PLC Has $12.07 Million Stake in DaVita Inc. $DVA

Hsbc Holdings PLC decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 40.8% in the 1st quarter, HoldingsChannel.com reports. The fund owned 78,790 shares of the company’s stock after selling 54,290 shares during the quarter. Hsbc Holdings PLC’s holdings in DaVita were worth $12,069,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC grew its stake in DaVita by 27.4% in the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after acquiring an additional 45,609 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its stake in DaVita by 63.5% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company’s stock worth $9,770,000 after purchasing an additional 33,394 shares in the last quarter. Los Angeles Capital Management LLC lifted its stake in DaVita by 132.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 24,322 shares of the company’s stock valued at $2,888,000 after buying an additional 13,847 shares in the last quarter. LSV Asset Management increased its position in shares of DaVita by 1.1% during the fourth quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after acquiring an additional 9,739 shares in the last quarter. Finally, M&T Bank Corp boosted its stake in DaVita by 694.7% in the 4th quarter. M&T Bank Corp now owns 22,307 shares of the company’s stock worth $2,534,000 after purchasing an additional 19,500 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on DVA shares. TD Cowen raised their price target on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. UBS Group lifted their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Finally, Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and increased their price objective for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DaVita has an average rating of “Hold” and an average target price of $216.50.

Insiders Place Their Bets

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.90% of the stock is currently owned by corporate insiders.

DaVita Stock Performance

NYSE:DVA opened at $231.56 on Thursday. The company has a market cap of $14.87 billion, a price-to-earnings ratio of 21.48, a PEG ratio of 0.78 and a beta of 0.88. The stock has a fifty day moving average price of $212.06 and a 200-day moving average price of $167.40. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $239.64.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the business posted $2.00 EPS. The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.